You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 238 No. 19, November 7, 1977 TABLE OF CONTENTS
  JAMA
  •  Online Features
  CLINICAL NOTES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (21)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Growth Velocity in a Child on Prolonged Hemodialysis

Beneficial Effect of 1-{alpha}-Hydroxyvitamin D3

James C. M. Chan, MD; Hector F. DeLuca, PhD

JAMA. 1977;238(19):2053-2054.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

SECONDARY hyperparathyroidism, renal osteodystrophy, and growth failure nearly invariably develop in children on prolonged hemodialysis.1-3 We report our experience with a child who showed acceleration of growth velocity in response to treatment with the analogue (1-{alpha}-hydroxyvitamin D3) of the kidney hormone, 1,25 dihydroxyvitamin D3 (1,25-[OH]2-D3).

Report of a Case

An 11-year-old girl entered the hemodialysis program for irreversible end-stage kidney failure secondary to focal segmental glomerulosclerosis. Over the next four years, she received four to six hours of dialysis treatment three times per week on parallel flow and/or coil disposable dialyzers. Vascular access, dialysis procedures, delivery system, and dietary and antihypertensive therapy were identical to the standard methods previously reported from this unit.1,4,5 The caloric and protein intakes at 12,13, and 14 years of age are shown in the Table.

Treatment with 1-{alpha}-hydroxyvitamin D3 (1-{alpha}-OH-D3) was initiated four months prior to . . . [Full Text PDF of this Article]


Author Affiliations

From the Section on Steroid and Mineral Metabolism, Hypertension-Endocrine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md (Dr Chan), and the Department of Biochemistry, University of Wisconsin, Madison (Dr DeLuca).


Footnotes

Reprint requests to Section on Steroid and Mineral Metabolism, Hypertension-Endocrine Branch, National Heart, Lung, and Blood Institute, Bldg 10, Room 8 N-214, National Institutes of Health, Bethesda, MD 20014 (Dr Chan).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1977 American Medical Association. All Rights Reserved.